2017
DOI: 10.21037/hbsn.2016.08.04
|View full text |Cite
|
Sign up to set email alerts
|

Follicular dendritic cell sarcoma of the liver with metachronous small bowel and splenic metastases: a case report and literature review

Abstract: Follicular dendritic cell sarcoma (FDCS) of the liver is an extremely rare disease, accounting for a mere 0.4% of all soft tissue sarcomas. FDCS most commonly involves lymph nodes but also affects extranodal sites such as the gastrointestinal system, oral cavity, liver, spleen and pancreas, albeit less commonly. It is widely considered a low-to-intermediate grade malignancy. We report a case of FDCS with metachronous involvement of the liver, small intestines and spleen, its imaging, histological findings and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 16 publications
(26 reference statements)
0
1
0
Order By: Relevance
“…However, it is essential to be vigilant about FDCS as a distinct entity, due risk of recurrence, or metastases. FDCS are shown to be hypermetabolic and observed as avid spots on positron emission tomography scan 9. Rarity of FDCS to affect extranodal solid organs, serves as an obligation to report experience of single cases, as this adds to the understanding of natural history and behavior of these rare neoplasms.…”
Section: Discussionmentioning
confidence: 99%
“…However, it is essential to be vigilant about FDCS as a distinct entity, due risk of recurrence, or metastases. FDCS are shown to be hypermetabolic and observed as avid spots on positron emission tomography scan 9. Rarity of FDCS to affect extranodal solid organs, serves as an obligation to report experience of single cases, as this adds to the understanding of natural history and behavior of these rare neoplasms.…”
Section: Discussionmentioning
confidence: 99%